Literature DB >> 14583483

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Paul A Clarke1, Mark L George, Sandra Easdale, David Cunningham, R Ian Swift, Mark E Hill, Diana M Tait, Paul Workman.   

Abstract

Global gene expression profiling has potential for elucidating the complex cellular effects and mechanisms of action of novel targeted anticancer agents or existing chemotherapeutics for which the precise molecular mechanism of action may be unclear. In this study, decreased expression of genes required for RNA and protein synthesis, and for metabolism were detected in rectal cancer biopsies taken from patients during a 5-fluorouracil infusion. Our observations demonstrate that this approach is feasible and can detect responses that may have otherwise been missed by conventional methods. The results suggested new mechanism-based combination treatments for colorectal cancer and demonstrated that expression profiling could provide valuable information on the molecular pharmacology of established and novel drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.

Authors:  Marian Grade; Patrick Hörmann; Sandra Becker; Amanda B Hummon; Danny Wangsa; Sudhir Varma; Richard Simon; Torsten Liersch; Heinz Becker; Michael J Difilippantonio; B Michael Ghadimi; Thomas Ried
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

Authors:  B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.

Authors:  Heekyung Chung; Joy Chaudhry; Claudia G Lopez; John M Carethers
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

4.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

5.  Proteomic changes during intestinal cell maturation in vivo.

Authors:  Jinsook Chang; Mark R Chance; Courtney Nicholas; Naseem Ahmed; Sandra Guilmeau; Marta Flandez; Donghai Wang; Do-Sun Byun; Shannon Nasser; Joseph M Albanese; Georgia A Corner; Barbara G Heerdt; Andrew J Wilson; Leonard H Augenlicht; John M Mariadason
Journal:  J Proteomics       Date:  2008-09-12       Impact factor: 4.044

6.  5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.

Authors:  Janindra Warusavitarne; Palaniappan Ramanathan; Anthony Kaufman; Bruce G Robinson; Margaret Schnitzler
Journal:  Int J Colorectal Dis       Date:  2006-03-24       Impact factor: 2.571

7.  Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments?

Authors:  J Caradec; N Sirab; D Revaud; C Keumeugni; S Loric
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

8.  Cancer cell adaptation to chemotherapy.

Authors:  Federica Di Nicolantonio; Stuart J Mercer; Louise A Knight; Francis G Gabriel; Pauline A Whitehouse; Sanjay Sharma; Augusta Fernando; Sharon Glaysher; Silvana Di Palma; Penny Johnson; Shaw S Somers; Simon Toh; Bernie Higgins; Alan Lamont; Tim Gulliford; Jeremy Hurren; Constantinos Yiangou; Ian A Cree
Journal:  BMC Cancer       Date:  2005-07-18       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.